119 related articles for article (PubMed ID: 6854723)
1. Perfluorochemicals as liver- and spleen-seeking ultrasound contrast agents.
Mattrey RF; Leopold GR; vanSonnenberg E; Gosink BB; Scheible FW; Long DM
J Ultrasound Med; 1983 Apr; 2(4):173-6. PubMed ID: 6854723
[TBL] [Abstract][Full Text] [Related]
2. Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results.
Mattrey RF; Strich G; Shelton RE; Gosink BB; Leopold GR; Lee T; Forsythe J
Radiology; 1987 May; 163(2):339-43. PubMed ID: 3550878
[TBL] [Abstract][Full Text] [Related]
3. Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material.
Mattrey RF; Scheible FW; Gosink BB; Leopold GR; Long DM; Higgins CB
Radiology; 1982 Dec; 145(3):759-62. PubMed ID: 7146409
[TBL] [Abstract][Full Text] [Related]
4. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB
Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
[TBL] [Abstract][Full Text] [Related]
5. The influence of oxygenation on the 19F spin-lattice relaxation rates of fluosol-DA.
Reid RS; Koch CJ; Castro ME; Lunt JA; Treiber EO; Boisvert DJ; Allen PS
Phys Med Biol; 1985 Jul; 30(7):677-86. PubMed ID: 4023055
[TBL] [Abstract][Full Text] [Related]
6. Effects of a perfluorocarbon emulsion, Fluosol-DA, on rat lymphoid tissue and immunological competence.
Bollands AD; Lowe KC
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1986; 85(2):309-12. PubMed ID: 2879690
[TBL] [Abstract][Full Text] [Related]
7. Increased radiosensitivity of tumors by perfluorochemicals and carbogen.
Song CW; Zhang WL; Pence DM; Lee I; Levitt SH
Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1833-6. PubMed ID: 3930442
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
Teicher BA; Holden SA; Northey D; Dewhirst MW; Herman TS
Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):103-9. PubMed ID: 8482616
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal circulation with perfluorochemicals (Fluosol-DA).
Hoshino S; Iwaya F; Igari T; Kanno M; Honda K
J Cardiovasc Surg (Torino); 1982; 23(6):463-9. PubMed ID: 7153234
[TBL] [Abstract][Full Text] [Related]
10. Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocytes.
Kolodgie FD; Farb A; Carlson GC; Wilson PS; Virmani R
J Am Coll Cardiol; 1994 Oct; 24(4):1098-108. PubMed ID: 7930204
[TBL] [Abstract][Full Text] [Related]
11. [An experimental study on the effect of fluorocarbon perfusion for the preservation of an amputated limb].
Takahashi F
Nihon Seikeigeka Gakkai Zasshi; 1987 Oct; 61(10):1123-34. PubMed ID: 3437177
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different perfluorocarbons as ultrasound contrast agents.
Satterfield R; Tarter VM; Schumacher DJ; Tran P; Mattrey RF
Invest Radiol; 1993 Apr; 28(4):325-31. PubMed ID: 8478173
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent reduction of myocardial infarct size with the perfluorochemical Fluosol-DA.
Rice HE; Virmani R; Hart CL; Kolodgie FD; Farb A
Am Heart J; 1990 Nov; 120(5):1039-46. PubMed ID: 2239656
[TBL] [Abstract][Full Text] [Related]
14. Ultrasonic enhancement of myocardial infarction with perfluorocarbon compounds in dogs.
Mattrey RF; Andre MP
Am J Cardiol; 1984 Jul; 54(1):206-10. PubMed ID: 6741815
[TBL] [Abstract][Full Text] [Related]
15. Preservation of left ventricular ejection fraction during percutaneous transluminal coronary angioplasty by distal transcatheter coronary perfusion of oxygenated Fluosol DA 20%.
Jaffe CC; Wohlgelernter D; Cabin H; Bowman L; Deckelbaum L; Remetz M; Cleman M
Am Heart J; 1988 Jun; 115(6):1156-64. PubMed ID: 2967624
[TBL] [Abstract][Full Text] [Related]
16. In vivo 19F NMR imaging.
McFarland E; Koutcher JA; Rosen BR; Teicher B; Brady TJ
J Comput Assist Tomogr; 1985; 9(1):8-15. PubMed ID: 3968284
[TBL] [Abstract][Full Text] [Related]
17. Failure of fluosol DA to enhance the ultrasonic image of infarcted myocardium.
Vasey CG; Armstrong WF; West SR; Waller BF; Dillon JC; Feigenbaum H
J Clin Ultrasound; 1986 Oct; 14(8):613-8. PubMed ID: 3095392
[TBL] [Abstract][Full Text] [Related]
18. Increase in tumor pO2 by perfluorochemicals and carbogen.
Hasegawa T; Rhee JG; Levitt SH; Song CW
Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):569-74. PubMed ID: 3104250
[TBL] [Abstract][Full Text] [Related]
19. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases.
Mitsuno T; Ohyanagi H; Naito R
Ann Surg; 1982 Jan; 195(1):60-9. PubMed ID: 7034658
[TBL] [Abstract][Full Text] [Related]
20. Perfluoroctylbromide: a reticuloendothelial-specific and tumor-imaging agent for computed tomography.
Mattrey RF; Long DM; Multer F; Mitten R; Higgins CB
Radiology; 1982 Dec; 145(3):755-8. PubMed ID: 7146408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
